AJMC September 4, 2024
Pearl Steinzor

According to some reports, the draft rule imposes strict limitations on telehealth prescriptions even as advocates push for extension of current flexibilities.

The Drug Enforcement Administration (DEA) is nearing the final stages of its rulemaking process for prescribing controlled substances via telehealth, but leaked details reveal a more restrictive approach than anticipated.1

While advocates are once again lobbying the White House and Congress to extend a waiver on the use of telemedicine to prescribe medications, leaked details suggest this prescribing route will be limited, according to anonymous sources speaking to Fierce Healthcare and Politico.1,2

The telehealth prescribing flexibility rule has been used since 2020 to prescribe medications for conditions such as substance abuse disorder and attention deficit disorder. Last year,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, Govt Agencies, Mental Health, Patient / Consumer, Provider, Technology, Telehealth
Related Articles:
Direct-to-Consumer Drugs: Big Pharma's Digital Health Play
NCQA launches roadmap for virtual care accreditation
SUD Executives Hope for Permanent Telehealth Prescribing Flexibilities Amid DEA Uncertainty
Telehealth groups urge Congress, White House to extend controlled substance virtual prescribing
300+ Provider Organizations Urge Feds to Prevent Leaked DEA Rule From Going into Effect

Share This Article